JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million

Stock News

2025/11/17

JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.

The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182754508"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182754508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182754508?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182754508","market":"hk","top_or_hot":-1,"title":"JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million","media":"Stock News","content":"<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-17 18:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02161","symbol_name":"健倍苗苗","start_time":0,"source_url":"","article_id":"1182754508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182754508","pubTimestamp":1763376026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02161":"健倍苗苗","BK1191":"制药","BK1606":"中医药概念"},"translate_title":"健邦医疗(02161)公布中期业绩：权益持有人应佔溢利按年升20.0%至约1.15亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02161":1},"content_text":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.\nThe company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}